Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Carna Biosciences, Inc. (4572.T)
Kobe, JP
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.76% | +16.71% | +11.62% | +48.71% | +119.52% | +14.68% | +74.62% | -44.32% | -62.85% | -84.66% | -55.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-9.0% Q1'26: +28.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+6.6% Q1'26: -2.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-385.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-358.3% Q1'26: -249.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-409.3% Q1'26: -331.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.7% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.34× Q1'26: -1.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.57B
est: 1.52B (+3.2%)
|
811.60M
est: 800.00M (+1.4%)
|
657.52M
est: 683.50M (-3.8%)
|
754.69M
est: 750.00M (+0.6%)
|
3.21B
est: 3.16B (+1.4%)
|
1.13B
est: 1.10B (+3.0%)
|
2.02B
est: 1.46B (+38.0%)
|
1.39B
est: 1.22B (+13.7%)
|
1.63B
est: 3.60B (-54.8%)
|
636.24M
est: 3.70B (-82.8%)
|
579.06M
est: 3.60B (-83.9%)
|
| EBITDA |
507.60M
est: -1.16B (+143.9%)
|
-258.85M
est: -608.87M (+57.5%)
|
-714.36M
est: -520.20M (-37.3%)
|
-1.18B
est: -570.81M (-107.3%)
|
930.62M
est: -2.41B (+138.6%)
|
-1.08B
est: -837.19M (-29.3%)
|
-509.41M
est: -1.11B (+54.2%)
|
-1.28B
est: -928.52M (-38.3%)
|
-1.09B
est: -2.74B (+60.2%)
|
-2.14B
est: -2.85B (+24.9%)
|
-2.07B
est: -2.77B (+25.1%)
|
| EBIT |
488.38M
est: -1.18B (+141.5%)
|
-283.27M
est: -619.54M (+54.3%)
|
-726.48M
est: -529.32M (-37.2%)
|
-1.20B
est: -580.82M (-105.9%)
|
921.22M
est: -2.45B (+137.6%)
|
-1.10B
est: -851.87M (-28.6%)
|
-528.57M
est: -1.13B (+53.3%)
|
-1.32B
est: -944.80M (-39.5%)
|
-1.13B
est: -2.79B (+59.6%)
|
-2.17B
est: -2.89B (+24.9%)
|
-2.07B
est: -2.81B (+26.2%)
|
| Net Income |
456.39M
est: 832.82M (-45.2%)
|
-289.94M
est: -585.66M (+50.5%)
|
-737.26M
est: -1.34B (+45.1%)
|
-1.21B
est: -2.23B (+45.6%)
|
828.29M
est: 882.96M (-6.2%)
|
-1.11B
est: -1.83B (+39.4%)
|
-534.47M
est: -1.70B (+68.6%)
|
-1.35B
est: -2.29B (+41.0%)
|
-1.15B
est: 2.02B (-157.1%)
|
-2.18B
est: 2.30B (-194.8%)
|
-2.17B
|
| SGA |
409.58M
est: 795.75M (-48.5%)
|
467.72M
est: 418.82M (+11.7%)
|
463.21M
est: 357.83M (+29.5%)
|
507.67M
est: 392.64M (+29.3%)
|
740.08M
est: 1.66B (-55.3%)
|
523.81M
est: 575.87M (-9.0%)
|
571.42M
est: 765.13M (-25.3%)
|
602.77M
est: 638.70M (-5.6%)
|
663.72M
est: 1.88B (-64.8%)
|
654.89M
est: 4.74B (-86.2%)
|
2.46B
est: 4.61B (-46.6%)
|
| EPS |
52.61
est: 46.50 (+13.1%)
|
-31.64
est: -32.70 (+3.2%)
|
-78.53
est: -75.00 (-4.7%)
|
-125.02
est: -124.30 (-0.6%)
|
76.05
est: 49.30 (+54.3%)
|
-90.33
est: -102.30 (+11.7%)
|
-42.10
est: -95.15 (+55.8%)
|
-99.10
est: -127.70 (+22.4%)
|
-68.62
est: 112.70 (-160.9%)
|
-121.64
est: 120.20 (-201.2%)
|
-113.62
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akinori Arimura | GM of Clinical Development, R&D, Chief Development Officer of CarnaBio USA & Director | — | — |
| Emi Yamamoto | GM of Business Mgt., Accounting, HR, General Affairs, Chief Financial Officer, Director & President - CarnaBio USA | — | female |
| Kohichiro Yoshino | Chief Executive Officer, President & Representative Director | — | — |
| Kunihisa Masuoka | Chief Legal Officer & Director | — | male |
| Masaaki Sawa | GM of Research & Development Division, Chief Scientific Officer and Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4572.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
